LuMind IDSC Statement on CMS Proposed Coverage for Anti-Amyloid AD Drugs
January 12, 2022 During the past year, LuMind IDSC remained cautiously optimistic about treatment possibilities that the development of new drugs
January 12, 2022
January 12, 2022 During the past year, LuMind IDSC remained cautiously optimistic about treatment possibilities that the development of new drugs
RELIABLE DOWN SYNDROME RESOURCES FOR EVERY FAMILY, FOR EVERY STAGE OF LIFE “Down syndrome research is of huge importance to
This is about Down syndrome businesses – that is, businesses which are owned by people with Down syndrome, or by
Have you ever wondered what certain scientific terms or acronyms mean? If you’re interested in the scientific advances working towards
In this webinar, we chat with Stephanie Thompson, Director of the National Down Syndrome Adoption Network about the process of
November 4, 2021 In January 2018, amidst the celebration of the birth of their baby daughter, Roberto and Nayeli Ojeda
In June of 2021, the FDA approved a new drug, Aduhelm, from the company Biogen for the treatment of mild
Dr. Nicole White, Hampus Hillerstrom, LuMind IDSC and a team of experts, recently published an article in the Journal of Applied
In June, the FDA granted “accelerated approval” to Biogen’s Aduhelm drug. This is the first new drug approved for Alzheimer’s
October 7, 2021 From mom of four to Down syndrome researcher. Research Spotlight sat with Nicole White and discussed some